Author:
Abounouh Karima,Ouladlahsen Ahd,Altawalah Haya,Rabaan Ali A.,Dehbi Hind,Guessous Fadila,Ezzikouri Sayeh
Publisher
Springer Nature Singapore
Reference163 articles.
1. Abounouh K, Aitraise I, Benabou A, Boussakri I, Doumir MA, El Boussairi C, El Idrissi S, El Mahdaoui C, Qouar DE, Ennahal A, Fathi S, Hafidi M, Lachker L, Ratib C, Tanouti IA, Maaroufi A, Benjelloun S, Guessous F, Pineau P, Ezzikouri S (2019) Virus-associated human cancers in Moroccan population: from epidemiology to prospective research. Infect Genet Evol 75:103990. https://doi.org/10.1016/j.meegid.2019.103990
2. Abramson JS, Chung RT (2014) Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. JAMA 312(23):2505–2507. https://doi.org/10.1001/jama.2014.16095
3. Agarwal K, Afdhal N, Coffin C, Fung S, Dusheiko G, Foster G, Elkhashab M, Tam E, Ramji A, Iyer R (2020) Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients. J Hepatol 73:S125
4. Anderson RT, Lim SG, Mishra P, Josephson F, Donaldson E, Given B, Miller V (2019) Challenges, considerations, and principles to guide trials of combination therapies for chronic hepatitis B virus. Gastroenterology 156(3):529–533 e524. https://doi.org/10.1053/j.gastro.2018.11.062
5. Atsama Amougou M, Marchio A, Bivigou-Mboumba B, Noah Noah D, Banai R, Atangana PJA, Fewou Moundipa P, Pineau P, Njouom R (2019) Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon. J Viral Hepat 26(9):1086–1093. https://doi.org/10.1111/jvh.13131